Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.50 |
| ▸ | ABAT | P80404 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9318675 | 0.88 | ALDH1A1 (0.44) | ALDH1A1MAPK1GPR35TP53HPGD | |
| SCHEMBL7108888 | 0.85 | SMN1; SMN2 (0.58) | ALDH1A1MAPK1GPR35TP53HPGD | |
| SCHEMBL9318677 | 0.85 | TSHR (0.43) | ALDH1A1MAPK1GPR35TP53HPGD | |
| SCHEMBL21695808 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1GPR35TP53HPGD | |
| SCHEMBL21695800 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1GPR35TP53HPGD | |
| SCHEMBL21260572 | 0.80 | TSHR (0.55) | ALDH1A1MAPK1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL2080018 | 0.79 | VCAM1 (0.50) | ALDH1A1MAPK1HPGDTSHRMAPT | |
| SCHEMBL11655004 | 0.79 | TSHR (0.58) | ALDH1A1HPGDTSHRSMN1; SMN2ALOX15 | |
| SCHEMBL9222965 | 0.79 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2CA1MAPTLMNA | |
| SCHEMBL6514054 | 0.79 | TSHR (0.36) | ALDH1A1MAPK1GPR35TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920004-B2 | Method for producing phenolic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-03-20 | — | — | US | disclosed |
| US-20170137377-A1 | METHOD FOR PRODUCING PHENOLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-18 | — | — | US | disclosed |
| US-9615580-B2 | Fused heterocyclic compound and use thereof for pest control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-04-11 | — | — | US | disclosed |
| US-20150313234-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
| US-6046183-A | SYNERGISTIC MIXTURE OF FINASTERIDE AND DOXAZOSIN | MERCK & CO., INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5994362-A | ADMINISTERING FINASTERIDE AND CASODEX | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5753641-A | SYNERGISTIC THERAPY COMPRISING FINASTERIDE AND TERAZOSIN DRUGS | MERCK & CO., INC. (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0526093-A1 | New non-steroidal agents as 5-alpha reductase inhibitors | MERCK & CO. INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137377-A1 | METHOD FOR PRODUCING PHENOLIC COMPOUND | HAO2, AOX1, QSOX1 | ALDH1A1 166/4885MAPK1 550/4885GPR35 3971/4885 |
| US-20150313234-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL | AFF1, AFF2, PYM1 | ALDH1A1 1355/4885MAPK1 1836/4885GPR35 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.